Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1959 1
1963 1
1964 3
1965 3
1966 1
1967 2
1968 6
1969 6
1970 5
1971 12
1972 11
1973 4
1974 3
1975 8
1976 7
1977 4
1978 11
1979 15
1980 19
1981 10
1982 11
1983 20
1984 22
1985 27
1986 24
1987 20
1988 24
1989 17
1990 19
1991 22
1992 26
1993 20
1994 23
1995 35
1996 46
1997 36
1998 34
1999 24
2000 25
2001 30
2002 28
2003 34
2004 32
2005 39
2006 40
2007 38
2008 62
2009 81
2010 72
2011 71
2012 101
2013 92
2014 95
2015 100
2016 102
2017 110
2018 138
2019 142
2020 163
2021 161
2022 178
2023 164
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

2,473 results

Results by year

Filters applied: . Clear all
Page 1
Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort.
Korenblik R, Heil J, Smits J, James S, Olij B, Bechstein WO, Bemelmans MHA, Binkert CA, Breitenstein S, Williams M, Detry O, Dewulf MJL, Dili A, Grochola LF, Grote J, Heise D, Kalil JA, Metrakos P, Neumann UP, Pappas SG, Pennetta F, Schnitzbauer AA, Tasse JC, Winkens B, Olde Damink SWM, van der Leij C, Schadde E, van Dam RM; DRAGON trials collaborative. Korenblik R, et al. Br J Surg. 2024 Apr 3;111(4):znae087. doi: 10.1093/bjs/znae087. Br J Surg. 2024. PMID: 38662462 Free PMC article.
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. Among authors: ryan s. NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8. NPJ Breast Cancer. 2024. PMID: 38627457 Free PMC article.
2,473 results